Literature DB >> 10812724

Disease eradication as a public health strategy: a case study of poliomyelitis eradication.

R B Aylward1, H F Hull, S L Cochi, R W Sutter, J M Olivé, B Melgaard.   

Abstract

Disease eradication as a public health strategy was discussed at international meetings in 1997 and 1998. In this article, the ongoing poliomyelitis eradication initiative is examined using the criteria for evaluating candidate diseases for eradication proposed at these meetings, which covered costs and benefits, biological determinants of eradicability (technical feasibility) and societal and political considerations (operational feasibility). The benefits of poliomyelitis eradication are shown to include a substantial investment in health services delivery, the elimination of a major cause of disability, and far-reaching intangible effects, such as establishment of a "culture of prevention". The costs are found to be financial and finite, despite some disturbances to the delivery of other health services. The "technical" feasibility of poliomyelitis eradication is seen in the absence of a non-human reservoir and the presence of both an effective intervention and delivery strategy (oral poliovirus vaccine and national immunization days) and a sensitive and specific diagnostic tool (viral culture of specimens from acute flaccid paralysis cases). The certification of poliomyelitis eradication in the Americas in 1994 and interruption of endemic transmission in the Western Pacific since March 1997 confirm the operational feasibility of this goal. When the humanitarian, economic and consequent benefits of this initiative are measured against the costs, a strong argument is made for eradication as a valuable disease control strategy.

Entities:  

Keywords:  Case Studies; Cost Benefit Analysis; Delivery Of Health Care; Diseases; Evaluation; Health; Health Services; Immunization; Organization And Administration; Poliomyelitis--prevention and control; Primary Health Care; Program Evaluation; Programs; Quantitative Evaluation; Research Methodology; Studies; Viral Diseases; World

Mesh:

Substances:

Year:  2000        PMID: 10812724      PMCID: PMC2560720     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  12 in total

1.  When is a disease eradicable? 100 years of lessons learned.

Authors:  B Aylward; K A Hennessey; N Zagaria; J M Olivé; S Cochi
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  Impact of targeted programs on health systems: a case study of the polio eradication initiative.

Authors:  Benjamin Loevinsohn; Bruce Aylward; Robert Steinglass; Ellyn Ogden; Tracey Goodman; Bjorn Melgaard
Journal:  Am J Public Health       Date:  2002-01       Impact factor: 9.308

3.  Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.

Authors:  Javier Martín; Elena Samoilovich; Glynis Dunn; Angie Lackenby; Esphir Feldman; Alan Heath; Ekaterina Svirchevskaya; Gill Cooper; Marina Yermalovich; Philip D Minor
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Immunity to poliovirus serotypes in children population of selected communities in South-west, Nigeria.

Authors:  Johnson Adekunle Adeniji; Folakemi Abiodun Osundare; Olubusuyi Moses Adewumi; Anyebe Bernard Onoja; Ademola Hezekiah Fagbami
Journal:  Afr J Infect Dis       Date:  2015

Review 5.  How absolute is zero? An evaluation of historical and current definitions of malaria elimination.

Authors:  Justin M Cohen; Bruno Moonen; Robert W Snow; David L Smith
Journal:  Malar J       Date:  2010-07-22       Impact factor: 2.979

6.  Long-term circulation of vaccine-derived poliovirus that causes paralytic disease.

Authors:  Elena A Cherkasova; Ekaterina A Korotkova; Maria L Yakovenko; Olga E Ivanova; Tatyana P Eremeeva; Konstantin M Chumakov; Vadim I Agol
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 7.  From emergence to eradication: the epidemiology of poliomyelitis deconstructed.

Authors:  Neal Nathanson; Olen M Kew
Journal:  Am J Epidemiol       Date:  2010-10-26       Impact factor: 4.897

8.  Lung function in post-poliomyelitis syndrome: a cross-sectional study.

Authors:  Claudio Andre Barbosa de Lira; Fábio Carderelli Minozzo; Bolivar Saldanha Sousa; Rodrigo Luiz Vancini; Marília dos Santos Andrade; Abrahão Augusto Juviniano Quadros; Acary Souza Bulle Oliveira; Antonio Carlos da Silva
Journal:  J Bras Pneumol       Date:  2013 Jun-Aug       Impact factor: 2.624

Review 9.  The economics of malaria control and elimination: a systematic review.

Authors:  Rima Shretta; Anton L V Avanceña; Arian Hatefi
Journal:  Malar J       Date:  2016-12-12       Impact factor: 2.979

10.  The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV): facts, experiences and lessons learned from the south-south zone; Nigeria, April 2016.

Authors:  Bassey Enya Bassey; Fiona Braka; Rui Gama Vaz; William Komakech; Sylvester Toritseju Maleghemi; Richard Koko; Thompson Igbu; Faith Ireye; Sylvester Agwai; Godwin Ubong Akpan; Sisay Gashu Tegegne; Abdul-Aziz Garba Mohammed; Angela Okocha-Ejeko
Journal:  BMC Infect Dis       Date:  2018-01-27       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.